文献速递心脑血管急症

单核细胞趋化蛋白-1不能预测非低危胸痛患者的心脏事件

Monocyte chemoattractant protein-1 is not predictive of cardiac events in patients with non-low-risk chest pain.
PubMed 文献 · Emerg Med J · 2021-12-21
一句话结论在HEAR评分≥4或合并冠心病的非低危胸痛患者中,MCP-1不能预测90天主要不良心血管事件。

本研究为嵌套于前瞻性多中心队列(STOP-CP)的病例对照研究,纳入2017年1月25日至2018年9月6日美国8家急诊科收治的成人急性冠脉综合征评估患者,要求HEAR评分≥4或存在冠心病、心电图无缺血性改变、0和3小时当代肌钙蛋白不升高。共40例90天MACE病例与179例对照,两组年龄、性别、种族及HEAR评分/冠心病存在情况均无差异。MCP-1在病例组与对照组相似(中位数191.9 pg/mL vs 196.6 pg/mL,p=0.48),调整协变量后各切点均与90天MACE无关(194 pg/mL时OR 0.88,95%CI 0.43-1.79)。结论认为MCP-1不能预测此类患者的90天MACE。

要点

  • 在HEAR评分≥4或冠心病、心电图无缺血、0和3小时肌钙蛋白不升高的急诊胸痛患者中,MCP-1不能预测90天MACE。
  • MCP-1在90天MACE病例与对照组间无差异:中位数191.9 pg/mL(IQR 161.8-260.1)vs 196.6 pg/mL(IQR 163.0-261.1),p=0.48。
  • 切点194 pg/mL时,MCP-1预测90天MACE的敏感性50.0%(95%CI 33.8%-66.2%),特异性46.9%(95%CI 39.4%-54.5%)。
  • 调整年龄、性别、种族及HEAR评分/冠心病后,194 pg/mL切点OR 0.88(95%CI 0.43-1.79),各切点均无关联。
  • 模型中额外纳入高敏肌钙蛋白后,194 pg/mL切点OR 0.85(95%CI 0.42-1.73),MCP-1仍与90天MACE无关。

适用人群与场景

  • 纳入标准:因急性冠脉综合征在急诊科接受评估的成人患者,HEAR评分≥4或存在冠心病,心电图无缺血性改变,0和3小时当代肌钙蛋白不升高。
  • 研究场所:美国8家急诊科,2017年1月25日至2018年9月6日。
  • 研究设计为病例对照研究,嵌套于前瞻性多中心队列STOP-CP。

诊断标准与关键阈值

  • HEAR评分≥4或存在冠心病。
  • 心电图无缺血性改变。
  • 0和3小时当代肌钙蛋白不升高。
  • 90天MACE定义:全因死亡、心肌梗死或血运重建。

研究设计与关键结果

  • 研究类型:嵌套于前瞻性多中心队列(STOP-CP)的病例对照研究,纳入40例90天MACE病例和179例对照。
  • 两组年龄(p=0.90)、性别(p=1.00)、种族(p=0.85)、HEAR评分/冠心病存在情况(p=0.89)均无差异。
  • MCP-1在病例组中位数191.9 pg/mL(IQR 161.8-260.1),对照组中位数196.6 pg/mL(IQR 163.0-261.1),p=0.48。
  • 切点194 pg/mL时,MCP-1预测90天MACE的敏感性50.0%(95%CI 33.8%-66.2%),特异性46.9%(95%CI 39.4%-54.5%)。
  • 调整年龄、性别、种族及HEAR评分/冠心病后,194 pg/mL切点OR 0.88(95%CI 0.43-1.79),各切点均与90天MACE无关。
  • 模型中额外纳入高敏肌钙蛋白后,194 pg/mL切点OR 0.85(95%CI 0.42-1.73),MCP-1仍与90天MACE无关。

证据类型、等级与局限

  • 证据类型:病例对照研究(嵌套于前瞻性多中心队列)。
  • 研究检测了194 pg/mL、200 pg/mL、238 pg/mL和281 pg/mL四个切点,均未发现MCP-1与90天MACE的关联。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在HEAR评分≥4或存在冠心病、心电图无缺血性改变、0和3小时当代肌钙蛋白不升高的急诊胸痛患者中,MCP-1不能预测90天MACE,不宜用于此类患者的风险分层。
  • 原文结论未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Prior studies suggest monocyte chemoattractant protein-1 (MCP-1) may be useful for risk stratifying ED patients with chest pain. We hypothesise that MCP-1 will be predictive of 90-day major adverse cardiovascular events (MACEs) in non-low-risk patients.

METHODS: A case-control study was nested within a prospective multicentre cohort (STOP-CP), which enrolled adult patients being evaluated for acute coronary syndrome at eight US EDs from 25 January 2017 to 06 September 2018. Patients with a History, ECG, Age, and Risk factor score (HEAR score) ≥4 or coronary artery disease (CAD), a non-ischaemic ECG, and non-elevated contemporary troponins at 0 and 3 hours were included. Cases were patients with 90-day MACE (all-cause death, myocardial infarction or revascularisation). Controls were patients without MACE selected with frequency matching using age, sex, race, and HEAR score or the presence of CAD. Serum MCP-1 was measured. Sensitivity and specificity were determined for cut-off points of 194 pg/mL, 200 pg/mL, 238 pg/mL and 281 pg/mL. Logistic regression adjusting for age, sex, race, and HEAR score/presence of CAD was used to determine the association between MCP-1 and 90-day MACE. A separate logistic model also included high-sensitivity troponin (hs-cTnT).

RESULTS: Among 40 cases and 179 controls, there was no difference in age (p=0.90), sex (p=1.00), race (p=0.85), or HEAR score/presence of CAD (p=0.89). MCP-1 was similar in cases (median 191.9 pg/mL, IQR: 161.8-260.1) and controls (median 196.6 pg/mL, IQR: 163.0-261.1) (p=0.48). At a cut-off point of 194 pg/mL, MCP-1 was 50.0% (95% CI 33.8% to 66.2%) sensitive and 46.9% (95% CI 39.4% to 54.5%) specific for 90-day MACE. After adjusting for covariates, MCP-1 was not associated with 90-day MACE at any cut-off point (at 194 pg/mL, OR 0.88 (95% CI 0.43 to 1.79)). When including hs-cTnT in the model, MCP-1 was not associated with 90-day MACE at any cut-off point (at 194 pg/mL, OR 0.85 (95% CI 0.42 to 1.73)).

CONCLUSION: MCP-1 is not predictive of 90-day MACE in patients with non-low-risk chest pain.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Ashburn NP, Snavely AC, Allen BR, et al. Monocyte chemoattractant protein-1 is not predictive of cardiac events in patients with non-low-risk chest pain. Emerg Med J. 2021. PMID: 34933919. doi:10.1136/emermed-2021-211266

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。